Merck & Co Inc
NYSE:MRK
Merck & Co Inc
NYSE:MRK
Price:
130.99 USD
-0.15%
Market Closed
Updated:
May 21, 2024
EV/OCF
Enterprise Value to OCF
Enterprise Value to OCF
24.2
Current
16.6
Median
16.2
Industry
Higher
than median
Higher
than industry value
Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.
EV/OCF
=24.2
Enterprise Value
/
357.3B
Operating Cash Flow
14.8B
All Countries
| Market Cap | EV/OCF | ||||
|---|---|---|---|---|---|
| US |
|
Merck & Co Inc
NYSE:MRK
|
331.8B USD | 24.2 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 438.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
744.3B USD | 208.5 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 43.2 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 930.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364.1B USD | 15.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.5B GBP | 247.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 12.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 15.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | 25.4 | |
| FR |
|
Sanofi SA
PAR:SAN
|
111.8B EUR | 11.6 |
EV/OCF Forward Multiples
Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A
You don't have any saved screeners yet
